Start Date
June 7, 2024
Primary Completion Date
September 30, 2024
Study Completion Date
September 30, 2024
Brigatinib
"Brigatinib is administered for 3 years or until progression of disease, or unacceptable toxicities or withdrawal of consent, whatever occurs first. After the treatment period of 3 years, patient's ongoing treatment will be managed according to local standard and best clinical practice.~Brigatinib should be taken approximately at the same time each day. It may be taken with or without food. Patients shall be instructed to swallow the tablets whole and not crush or chew them."
Durvalumab
Patients in the control arm will be observational, or, as per investigators choice, patients may receive durvalumab, administered within the label in the respective country.
CHU Angers, Angers
Caen - CHU, Caen
Hôpital de Marseille, Marseille
IRCCS Instituto Tumori Giovanni Paolo II, Bari
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola
AOU Maggiore della Carità, Novara
Fondazione IRCCS Policlinico S. Matteo, Pavia
Santa Maria della Misericordia Hospital, Perugia
AULSS2 Marca Trevigiana Treviso, Treviso
Universita di Verona - Department of Medicine, Verona
Medical University Gdansk, Gdansk
Hospital Universitario Dr Balmis Alicante - ISABIAL, Alicante
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Vall d'Hebron, Barcelona
Hospital Universitario Basurto, Bilbao
Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera
Hospital Universitario Lucus Augusti, Lugo
H. Puerta de Hierro Majadahonda, Majadahonda
Royal Marsden Hospital (Fulham Road), London
Royal Marsden Hospital (Sutton), London
Collaborators (1)
Takeda
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK